Co-Authors
This is a "connection" page, showing publications co-authored by Andrzej Jakubowiak and Jennifer Cooperrider.
Connection Strength
0.701
-
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024 10 07; 14(1):170.
Score: 0.234
-
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024 05 29; 14(1):87.
Score: 0.228
-
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood Adv. 2025 May 07.
Score: 0.061
-
Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma. Blood Cancer J. 2025 Mar 28; 15(1):47.
Score: 0.060
-
Rapid high-dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma. EJHaem. 2024 Dec; 5(6):1260-1264.
Score: 0.059
-
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma. Blood. 2024 08 29; 144(9):955-963.
Score: 0.058